Arbaclofen - Seaside Therapeutics

Drug Profile

Arbaclofen - Seaside Therapeutics

Alternative Names: STX-209

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seaside Therapeutics
  • Developer Seaside Therapeutics; The Childrens Hospital of Philadelphia
  • Class Aminobutyric acids; Gastrokinetics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autistic disorder; Fragile X syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-0 development in Autistic-disorder(In adolescents) in USA (PO, Fast dissolve)
  • 05 Aug 2015 No recent reports on development identified - Phase-III for Fragile X syndrome (In adolescents, In adults) in USA (PO, fast dissolve tablet)
  • 05 Aug 2015 No recent reports on development identified - Phase-III for Fragile X syndrome (In adolescents, In children, In adults) in USA (PO, fast dissolve tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top